Skip to main content

Peer Review reports

From: Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study

Original Submission
17 Jul 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
12 Dec 2023 Reviewed Reviewer Report
14 Dec 2023 Reviewed Reviewer Report
26 Dec 2023 Reviewed Reviewer Report
19 Feb 2024 Author responded Author comments - H. J. Luijendijk
Resubmission - Version 3
19 Feb 2024 Submitted Manuscript version 3
20 Feb 2024 Author responded Author comments - H. J. Luijendijk
Resubmission - Version 4
20 Feb 2024 Submitted Manuscript version 4
7 Mar 2024 Reviewed Reviewer Report
9 Mar 2024 Reviewed Reviewer Report
27 Mar 2024 Author responded Author comments - H. J. Luijendijk
Resubmission - Version 5
27 Mar 2024 Submitted Manuscript version 5
28 Mar 2024 Author responded Author comments - H. J. Luijendijk
Resubmission - Version 6
28 Mar 2024 Submitted Manuscript version 6
10 Apr 2024 Reviewed Reviewer Report
3 Jun 2024 Author responded Author comments - H. J. Luijendijk
Resubmission - Version 7
3 Jun 2024 Submitted Manuscript version 7
3 Jun 2024 Author responded Author comments - H. J. Luijendijk
Resubmission - Version 8
3 Jun 2024 Submitted Manuscript version 8
Publishing
7 Jun 2024 Editorially accepted
22 Jun 2024 Article published 10.1186/s12874-024-02260-z

You can find further information about peer review here.

Back to article page